Search results for "Monoamine neurotransmitter"

showing 10 items of 29 documents

Selective α-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for parkinson’s disease

2018

Progressive neuronal death in brainstem nuclei and widespread accumulation of α-synuclein are neuropathological hallmarks of Parkinson’s disease (PD). Reduction of α-synuclein levels is therefore a potential therapy for PD. However, because α-synuclein is essential for neuronal development and function, α-synuclein elimination would dramatically impact brain function. We previously developed conjugated small interfering RNA (siRNA) sequences that selectively target serotonin (5-HT) or norepinephrine (NE) neurons after intranasal administration. Here, we used this strategy to conjugate inhibitory oligonucleotides, siRNA and antisense oligonucleotide (ASO), with the triple monoamine reuptake …

0301 basic medicineanimal diseasesDopamineOligonucleotidesGene ExpressionPharmacologySynaptic TransmissionPrefrontal cortexMiceDA neurotransmission0302 clinical medicineDrug DiscoveryMonoaminergicNeural PathwaysRNA Small InterferingCells Cultured5-HT neurotransmissionChemistryGene Transfer TechniquesParkinson DiseaseVentral tegmental areaSubstantia Nigramedicine.anatomical_structureCaudate putamenGene Knockdown Techniquesalpha-SynucleinMolecular MedicineRNA InterferenceOriginal ArticleMonoamine reuptake inhibitormedicine.drugSignal TransductionSerotoninSubstantia nigraASO03 medical and health sciencesProsencephalonα-synucleinDopamineIntranasal administrationGeneticsmedicineAnimalsHumansMolecular BiologyAdministration IntranasalPharmacologyPars compactaDopaminergic NeuronsGenetic TherapyCorpus Striatumnervous system diseases030104 developmental biologyMonoamine neurotransmitterGene Expression Regulationnervous systemsiRNAParkinson’s diseaseLocus coeruleus030217 neurology & neurosurgery
researchProduct

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors

2018

Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine. Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression or Parkinson's disease. Coumarin with a functionalized 3-phenyl ring system is a promising scaffold for building potent MAO-B inhibitors. Here, a vast set of 3-phenylcoumarin derivatives was designed using virtual combinatorial chemistry or rationally de novo and synthesized using microwave chemistry. The derivatives inhibited the MAO-B at 100 nM−1 μM. The IC50 value of the most potent derivative 1 was 56 nM. A docking-based structure-activi…

0301 basic medicineentsyymitParkinson's diseaseParkinsonin tautita311101 natural scienceslääkesuunnittelumonoamine oxidase B (MAO-B)lcsh:Chemistry03 medical and health scienceschemistry.chemical_compoundstructure-activity relationship (SAR)Dopamine3-phenylcoumarinmedicineStructure–activity relationshipoksidoreduktaasitkumariinitta116ta317inhibiittoritOriginal Researchchemistry.chemical_classificationbiologyvirtual drug designta1182General ChemistryCoumarin3. Good health0104 chemical sciences010404 medicinal & biomolecular chemistryChemistry030104 developmental biologyMonoamine neurotransmitterEnzymeBiochemistrychemistrylcsh:QD1-999Docking (molecular)biology.proteinParkinson’s diseaseMonoamine oxidase BMonoamine oxidase Amedicine.drugFrontiers in Chemistry
researchProduct

Repeated, Intermittent Social Defeat across the Entire Juvenile Period Resulted in Behavioral, Physiological, Hormonal, Immunological, and Neurochemi…

2016

The developing brain is vulnerable to social defeat during the juvenile period. As complements of human studies, animal models of social defeat provide a straightforward approach to investigating the functional and neurobiological consequences of social defeats. Taking advantage of agonist behavior and social defeat in male golden hamster, a set of 6 experiments was conducted to investigate the consequences at multiple levels in young adulthood resulting from repeated, intermittent social defeats or “social threats” across the entire juvenile period. Male hamsters at postnatal day 28 (P28) were randomly assigned to either the social defeat, “social threat”, or arena control group, and they …

0301 basic medicinesocial threatCognitive NeuroscienceHippocampusContext (language use)cortisolpro-inflammatory cytokinesrepeated intermittent social defeatDevelopmental psychologySocial defeat03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineNeurochemicalmonoamine neurotransmittersJuvenileYoung adultOriginal Researchmale golden hamstersSocial relationadolescent bullying030104 developmental biologyjuvenileNeuropsychology and Physiological PsychologyPsychology030217 neurology & neurosurgeryGolden hamsterNeuroscienceFrontiers in Behavioral Neuroscience
researchProduct

Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans

2004

BACKGROUND: St John's wort (Hypericum perforatum) is a popular over-the-counter antidepressant. Its antidepressive effect has been attributed in part to inhibition of monoamine transporters and monoamine oxidase, on the basis of in vitro studies. METHODS: In a double-blind, randomized, placebo-controlled, crossover study, 16 healthy subjects (11 men and 5 women; mean age, 31 +/- 5 years) ingested either St John's wort (300 mg three times daily) or placebo for 7 days. Imipramine treatment (50 mg three times daily) in 7 subjects served as a positive control. After treatment, physiologic and biochemical tests included cardiovascular reflex testing, graded head-up tilt testing, and plasma catec…

AdultMaleNitroprussideImipraminemedicine.medical_specialtyPosturePharmacologyAutonomic Nervous SystemPlaceboMethoxyhydroxyphenylglycolNorepinephrine uptakeCardiovascular Physiological PhenomenaNorepinephrineCatecholaminesDouble-Blind MethodInternal medicineHeart rateSupine PositionmedicineHumansNitric Oxide DonorsPharmacology (medical)PeryleneAnthracenesPharmacologyCross-Over StudiesAdrenergic Uptake Inhibitorsbusiness.industryHemodynamicsHypericum perforatumEndocrinologyBlood pressureMonoamine neurotransmitterCatecholamine34-Dihydroxyphenylacetic AcidAntidepressantFemalebusinessHypericummedicine.drugClinical Pharmacology & Therapeutics
researchProduct

Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. …

2009

Combining measurements of the monoamine metabolites in the cerebrospinal fluid (CSF) and neuroimaging can increase efficiency of drug discovery for treatment of brain disorders. To address this question, we examined five drug-naive patients suffering from schizophrenic disorder. Patients were assessed clinically, using the Positive and Negative Syndrome Scale (PANSS): at baseline and then at weekly intervals. Plasma and CSF levels of quetiapine and norquetiapine as well CSF 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindole-acetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were obtained at baseline and again after at least a 4 week medication trai…

AdultMalemedicine.medical_specialtyDibenzothiazepinesFluorine RadioisotopesPyrrolidinesmedicine.drug_classCaudate nucleusAtypical antipsychoticPilot ProjectsTritiumMethoxyhydroxyphenylglycolchemistry.chemical_compoundQuetiapine FumarateYoung AdultInternal medicinemedicineHumansBiogenic MonoaminesBiological PsychiatryTemporal cortexFirst episodeBrain Mappingbusiness.industryReceptors Dopamine D2Homovanillic acidHomovanillic AcidMiddle AgedMagnetic Resonance ImagingPsychiatry and Mental healthMonoamine neurotransmitterEndocrinologyFallypridechemistryPositron-Emission TomographyBenzamidesSchizophreniaQuetiapine34-Dihydroxyphenylacetic Acidbusinessmedicine.drugAntipsychotic AgentsProtein BindingJournal of psychiatric research
researchProduct

Norepinephrine transporter gene polymorphism is not associated with susceptibility to alcohol dependence

2002

Abnormalities in monoamine neurotransmission have been implicated in the pathogenesis of alcoholism, mood disorders and schizophrenia. Murine norepinephrine transporter gene (NET) has been mapped to a region on chromosome 8 where a quantitative trait locus for ethanol sensitivity. Therefore we tested whether norepinephrine transporter (NET) gene variants confer susceptibility to either alcohol dependence or severe alcohol withdrawal symptoms. There is a highly polymorphic silent G1287A mutation in the NET gene. In our study 157 alcoholics and 185 healthy unrelated matched control subjects were analyzed for a silent G1287A mutation. No significant differences in allele and genotype distribut…

AdultMalemedicine.medical_specialtyGenotypeDNA Mutational AnalysisMolecular Sequence DataAlcohol Withdrawal DeliriumGene FrequencyPolymorphism (computer science)Internal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseRNA MessengerAlleleAllelesBiological PsychiatryGeneticsNorepinephrine Plasma Membrane Transport ProteinsPolymorphism GeneticSymportersbiologybusiness.industryAlcohol dependenceExonsMiddle Agedmedicine.diseaseAlcoholismPsychiatry and Mental healthMonoamine neurotransmitterEndocrinologyMood disordersNorepinephrine transporterbiology.proteinFemaleGene polymorphismbusinessPolymorphism Restriction Fragment LengthPsychiatry Research
researchProduct

Intra-Nasally Administered Oligopeptide Lunasin Acts as a Possible Anti-Psychotic Agent in Mice Models

2019

Background and Objectives: Previously we have shown that synthetic lunasin, a 43 amino acid residue-containing peptide, after its central (intracisternal) administration in mice demonstrated antagonism against dopaminergic drug behavioural effects, indicating a putative antipsychotic/anti-schizophrenic profile of lunasin. The aims of the present studies were: to test whether lunasin would show an influence on the dopaminergic system after intranasal administration, and to examine the effect(s) of lunasin on serotonin and glutamatergic systems, which could play an essential role in antipsychotic action. Materials and Methods: Lunasin was administered intra-nasally at doses 0.1 and 1 nmol/mou…

AgonistMedicine (General)medicine.drug_classreceptor bindingbrain monoaminesPharmacologyMotor ActivityLunasinArticleintranasal administration03 medical and health sciencesMiceR5-9200302 clinical medicinehyper-locomotionmedicineAnimalslunasin; intranasal administration; hyper-locomotion; brain monoamines; receptor bindingAmphetaminePhencyclidine5-HT receptorAdministration IntranasalMice Inbred ICRChemistrylunasinAmphetaminesGeneral MedicineDisease Models AnimalMonoamine neurotransmitter030220 oncology & carcinogenesisNMDA receptorSerotoninOligopeptides030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsMedicina; Volume 55; Issue 7; Pages: 393
researchProduct

Grafted squaramide monoamine nanoparticles as simple systems for sulfate recognition in pure water.

2012

New simple systems formed by a chain containing a squaramide function and a quaternised amine group attached to boehmite or silica-coated boehmite nanoparticles are able to discriminate anions in pure water.

BoehmiteMetals and AlloysSquaramideNanoparticleGeneral ChemistryCatalysisSurfaces Coatings and FilmsElectronic Optical and Magnetic Materialschemistry.chemical_compoundMonoamine neurotransmitterchemistryPolymer chemistryMaterials ChemistryCeramics and CompositesOrganic chemistryAmine gas treatingSulfateChemical communications (Cambridge, England)
researchProduct

Brunner syndrome associated MAOA dysfunction in human dopaminergic neurons results in NMDAR hyperfunction and increased network activity

2020

AbstractBackgroundMonoamine neurotransmitter abundance affects motor control, emotion, and cognitive function and is regulated by monoamine oxidases. Amongst these, monoamine oxidase A (MAOA) catalyzes the degradation of dopamine, norepinephrine, and serotonin into their inactive metabolites. Loss-of-function mutations in the X-linked MAOA gene cause Brunner syndrome, which is characterized by various forms of impulsivity, maladaptive externalizing behavior, and mild intellectual disability. Impaired MAOA activity in individuals with Brunner syndrome results in bioamine aberration, but it is currently unknown how this affects neuronal function.MethodsWe generated human induced pluripotent s…

Brunner syndromeDopaminergicBiologymedicine.diseaseNorepinephrineMonoamine neurotransmitterDopaminebiology.proteinmedicineGRIN2BSerotoninMonoamine oxidase ANeurosciencemedicine.drug
researchProduct

Efficiency of antidepressant drugs as monoamine reuptake inhibitors: analysis of the hydrophobicity influence using biopartitioning micellar chromato…

2004

The reuptake blockade of biogenic amines by antidepressants is related not only to their therapeutics effects, but also to their side effects and potential drug-drug interactions. As an alternative to classical quantitative structure-activity relationships studies, in this work we propose different quantitative retention-activity relationships (QRAR) models that are able to describe the monoamine reuptake inhibition by antidepressants. The retention of compounds is measured using a biopartitioning micellar chromatography (BMC) system that can simulate the same hydrophobic, electronic and steric molecular interactions as those that condition drug activity. Since all the compounds considered …

Clinical BiochemistryPharmacologyBiochemistrySensitivity and SpecificityAnalytical ChemistryReuptakeStructure-Activity RelationshipDrug DiscoveryBiogenic MonoaminesNeurotransmitter Uptake InhibitorsMolecular BiologyMicellesPharmacologyMolecular interactionsChromatographyChemistryGeneral MedicineAntidepressive AgentsMonoamine neurotransmitterDrug activityAntidepressantSpectrophotometry UltravioletMonoamine reuptake inhibitorPharmacophoreReuptake inhibitorChromatography LiquidBiomedical chromatography : BMC
researchProduct